Dr. Jay Venkatesan, CEO, Angion, a clinical stage biopharmaceutical company, discusses the company's work in organ self-repair and their initial focus in the nephrology space.  The company's lead candidate ANG-3777 is a small molecule that mimics a protein to stimulate this self-repair and regeneration following injury. Angion's therapeutic programs modulate the natural repair pathways of the body to fill unmet medical needs across many indications, including acute kidney injury, kidney transplantation, and chronic kidney disease. #organinjury  #organtransplant  #acutekidneyinjury #chronickidneydisease Angion